Clover Biopharmaceuticals, Ltd.
Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-…
Biotechnology
CN, Shanghai [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 0.00 | 0.83 | 0.83 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -4.74 | 0.96 | 1.01 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Book Value | 0.00 | -0.59 | -0.59 | |
| Cash | 3.72 | 0.61 | 0.59 | |
| Capex | 0.00 | < 0.005 | < 0.005 | |
| Free Cash Flow | 0.00 | -0.12 | -0.12 | |
| Revenue | 0.00 | 0.02 | 0.02 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q3 | Q4 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 0.00 | -11.19 | -11.19 | |
| Operating Margin | 0.00 | -21.77 | -21.77 | |
| ROA | 0.00 | -0.19 | -0.19 | |
| ROE | 0.00 | 0.54 | 0.54 | |
| ROIC | 4.65 | 1.07 | 1.02 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of 2197.HK is permitted for members.
5
Growth
The "Growth Entry" for the Focus of 2197.HK is permitted for members.
6
Leverage & Liquidity